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Abstract Phosphorylation of CPI-17 by Rho-associated kinase
(Rho-kinase) and its effect on myosin phosphatase (MP) activity
were investigated. CPI-17 was phosphorylated by Rho-kinase to
0.92 mol of P/mol of CPI-17 in vitro. The inhibitory
phosphorylation site was Thr38 (as reported previously) and
was identified using a point mutant of CPI-17 and a
phosphorylation state-specific antibody. Phosphorylation by
Rho-kinase dramatically increased the inhibitory effect of CPI-
17 on MP activity. Thus, CPI-17 as a substrate of Rho-kinase
could be involved in the Ca2 sensitization of smooth muscle
contraction as a downstream effector of Rho-kinase. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
It is accepted that phosphorylation of the regulatory light
chain of myosin is an essential mechanism controlling con-
tractile activity in smooth muscle [1,2]. Increased Ca2 sensi-
tization is a well-known phenomenon observed in smooth
muscle contraction stimulated by agonists [2,3]. One expla-
nation for this e¡ect is via inhibition of myosin phosphatase
(MP) [4], which increases the level of myosin phosphorylation
and reinforces contraction at constant cytoplasmic calcium
[2,3]. The inhibition of MP following agonist stimulation is
transmitted through G-protein-coupled mechanisms and the
small GTPase RhoA plays a pivotal role in this process [3,5].
MP is composed of three subunits: a catalytic subunit, the
N isoform of the catalytic subunit of type 1 protein phospha-
tase (PP1cN), and two putative regulatory subunits, termed
MYPT1 and M20 [4]. A plausible mechanism to account for
the RhoA-induced inhibition of MP is by phosphorylation of
MYPT1 by Rho-associated kinase (Rho-kinase), a down-
stream target of RhoA [3^7]. Arachidonic acid also can induce
Ca2 sensitization and, at least in part, this is due to activa-
tion of Rho-kinase [3,8]. Another potential pathway to in-
crease Ca2 sensitization is by protein kinase C (PKC) acti-
vation and this is independent of the RhoA/Rho-kinase links
[3]. It was suggested that PKC inhibited MP by phosphory-
lation of CPI-17 [9].
CPI-17 is a phosphorylation-dependent inhibitory protein
for MP speci¢cally expressed in smooth muscle [9]. Phosphor-
ylation of CPI-17 at Thr38 by PKC enhances its inhibitory
potency about 1000-fold in vitro and the phosphorylated
CPI-17 could induce contraction in permeabilized smooth
muscle [10,11]. In an earlier report on CPI-17 [9], the kinase
involved showed some inconsistencies with PKC and thus
raised the possibility that another kinase could be implicated.
Recently, the phosphorylation of CPI-17 was demonstrated in
permeabilized vascular smooth muscle following agonist stim-
ulation. The phosphorylation was catalyzed by PKC and also
by a kinase sensitive to Y-27632, i.e. Rho-kinase or PKN [12].
Here we will show that CPI-17 is a substrate of Rho-kinase
in vitro and that the phosphorylation of Thr38 by Rho-kinase
converts CPI-17 into a more potent inhibitor of MP.
2. Materials and methods
2.1. Chemicals
[Q-32P]ATP (3000 Ci/mmol) was obtained from Du Pont-NEN;
phorbol 12-myristate 13-acetate and L-K-phosphatidyl-L-serine were
from Sigma Chemical Co.; and microcystin-LR was from Wako
Pure Chemical Co. All other chemicals were of reagent grade.
2.2. Protein preparations
Rho-kinase and kinase-free MP were prepared from chicken gizzard
[8]. CPI-17 was puri¢ed from porcine aorta as described previously
[9]. Other preparations were as follows: 20 kDa myosin light chain
(MLC20) [13] and myosin light chain kinase (MLCK) [14] from chick-
en gizzard; calmodulin from bovine brain [15]; PKC from human
platelets [16]; glutathione S-transferase (GST)-RhoA [8]; 32P-labelled
MLC20 phosphorylated by MLCK (32P-MLC20) [17].
2.3. Plasmid constructs and site-directed mutagenesis
cDNA encoding the open reading frame of CPI-17 was ampli¢ed
by nested PCR from a Vgt10 porcine aorta cDNA library (Clontech).
The primers used were based on the published sequence [18].
These were 5P-GCCGGGCCAGGACCGCGATGG-3P and 5P-CGG-
AGGGGGGTCACAGAGGCC-3P in the ¢rst PCR for 5P and 3P,
respectively, and 5P-GCCAGGGGATCCATGGCAGCTCAG-3P (un-
derlined residues show a BamHI site) and 5P-CCGGGGAATTCGT-
CAGGGCGGCGC-3P (underlined residues show an EcoRI site) in
the second PCR for 5P and 3P, respectively. PCR was carried using
Takara LA Taq1 with GC bu¡er I (Takara Shuzou) and the con-
ditions used were 94‡C for 30 s, 60‡C for 30 s, and 72‡C for 1 min for
30 cycles. The obtained PCR product was inserted into pCR2.1 vector
(Invitrogen) and veri¢ed by DNA sequencing. The full length CPI-17
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cDNA was retrieved from the vector as a BamHI^EcoRI fragment,
then subcloned into pGEX4T-1 vector (Amersham Pharmacia Bio-
tech) for the GST fusion protein (termed rG-CPI-17). To obtain the
plasmid for the His-tagged CPI-17 recombinant, cDNA for CPI-17
was re-ampli¢ed using the above plasmid (pGEX4T-1 vector ligated
with CPI-17 cDNA) as a template, Takara Ex Taq1 with EX bu¡er
(Takara Shuzou) and the following set of primers: 5P-GCCAGGGG-
ATCCATGGCAGCTCAG-3P (underlined residues show a BamHI
site) for 5P and 5P-CCGGGAAGCTTGTCAGGGCGGCGC-3P (un-
derlined residues show a HindIII site) for 3P. The conditions used were
94‡C for 30 s, 64‡C for 30 s, and 72‡C for 1 min for 30 cycles. The
obtained PCR product was digested as a BamHI^HindIII fragment,
then subcloned into the pQE30 vector (Qiagen) for the His-tagged
protein (termed rH-CPI-17). The ligated PCR product was veri¢ed
by DNA sequencing. The point mutant of CPI-17 at the inhibitory
phosphorylation site (substitution of Thr38 to Ala; termed rH-CPI-
17T38A) was created on a CPI-17 cDNA-ligated pQE30 vector using a
site-directed mutagenesis kit according to the manufacturer’s instruc-
tions (Clontech). The desired mutation was incorporated into one pair
of oligonucleotide primers, each complementary to opposite strands
of the parental DNA template. The selection primer used was 5P-
GAGTGCACGATATCCGGTGTGAAA-3P which was designed by
incorporating a two base change within a NdeI restriction site in
the original plasmid (underlined). The mutagenic primer was 5P-
GCGCGTGTCGCCGTCAAGTACGATCG-3P which was designed
by incorporating a one base change in CPI-17 cDNA (underlined,
original sequence was A). The mutant was selected by NdeI digestion
before the synthesized DNA was transformed into Escherichia coli
BMH 71-18 mutS. The sequence of the mutant was veri¢ed by
DNA sequencing.
2.4. Preparation of recombinant proteins and antibodies
rG-CPI-17 was expressed in E. coli BL21(DE3) strain and puri¢ed
on glutathione-Sepharose 4B according to the manufacturer’s instruc-
tions (Amersham Pharmacia Biotech). rH-CPI-17 and rH-CPI-17T38A
were expressed in E. coli M15 strain and puri¢ed on Ni-NTA agarose
according to the manufacturer’s instructions (Qiagen).
Rabbit polyclonal anti-CPI-17 antibody was raised against rG-CPI-
17. This antibody was a⁄nity-puri¢ed using a CNBr-activated
Sepharose 4B column (Amersham Pharmacia Biotech) coupled with
rH-CPI-17. For the site- and phosphorylation state-speci¢c antibody
against Thr38 in CPI-17, two peptides (Cys-Arg33-His-Ala-Arg-Val-
Thr38-Val-Lys-Tyr-Asp-Arg43 and Cys-Arg33-His-Ala-Arg-Val-phos-
pho-Thr38-Val-Lys-Tyr-Asp-Arg43) were synthesized and coupled
with keyhole limpet hemocyanin (Sawaday Co). The rabbit polyclonal
anti-phosphopeptide antibody was prepared and a⁄nity-puri¢ed as
described [7]. This antibody is referred to as pCPI-17T38.
2.5. Protein phosphorylation
Phosphorylation of native CPI-17 and recombinant rH-CPI-17 by
Rho-kinase was carried out at 30‡C for di¡erent times in 30 mM Tris^
HCl, pH 7.5, 30 mM KCl, 0.1 mM dithiothreitol, 1 mM MgCl2,
2 Wg/ml Rho-kinase, 2 WM guanosine 5P-3-O-(thio)triphosphate
(GTPQS)WGST-RhoA, 250 WM [Q-32P]ATP and 10 WM substrate as
indicated in a ¢nal volume of 30 Wl. The reactions were initiated by
addition of [Q-32P]ATP and terminated by addition of trichloroacetic
acid to 10%, followed by ¢ltration with 0.45 Wm nitrocellulose ¢lters
(Toyo Roshi). The ¢lters were extensively washed with 5% trichloro-
acetic acid and 32P incorporation was determined by Cerenkov count-
ing. To determine the e¡ects of phosphorylation of CPI-17 on MP
activity, phosphorylation of CPI-17 was carried out for 120 min under
similar conditions using non-radioactive ATP. The reactions were
boiled at 90‡C for 5 min, dialyzed against 30 mM Tris^HCl, pH
7.5, 30 mM KCl and 1 mM EDTA and assayed for phosphatase
activity. Phosphorylation of CPI-17 by PKC was carried out as fol-
lows: 10 WM native CPI-17 or recombinant rH-CPI-17 was incubated
at 30‡C for 120 min with 10 Wg/ml PKC in 30 mM Tris^HCl, pH 7.5,
1 mM MgCl2, 30 mM KCl, 1 mM EGTA, 100 ng/ml phorbol 12-
myristate 13-acetate, 100 Wg/ml L-K-phosphatidyl-L-serine and 250 WM
ATP.
2.6. Phosphatase assays
Phosphatase assays were carried out at 30‡C using 32P-MLC20 as
substrate (¢nal concentration 5 WM). Assay conditions were: 30 mM
Tris^HCl, pH 7.5, 100 mM KCl, 1 mM EDTA, 0.2 mg/ml bovine
serum albumin and 0.5 Wg/ml MP in the presence of various concen-
trations of CPI-17 as indicated. The reactions were started by the
addition of substrate and terminated by the addition of trichloroacetic
acid to 5%. After sedimentation at 5000Ug for 5 min, the radioactiv-
ity of the supernatant was determined by Cerenkov counting.
2.7. Other procedures
Sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) was carried out with the discontinuous bu¡er system of
Laemmli [19]. Western blotting was carried out as described previ-
ously [20]. Protein concentrations were determined with either the
BCA (Pierce) or Bradford (Bio-Rad) procedures, using bovine serum
albumin as a standard.
3. Results
To test if CPI-17 could be phosphorylated by Rho-kinase,
the time course and stoichiometry of phosphorylation by
Rho-kinase for native and recombinant CPI-17 were deter-
mined (Fig. 1). As shown in Fig. 1A, native CPI-17 was
phosphorylated by Rho-kinase to 0.92 þ 0.03 mol of P/mol
of CPI-17. Km, Vmax and kcat values of Rho-kinase for native
CPI-17 in the presence of the GTPQS-bound active form of
GST-RhoA and 200 WM ATP were 1.42 þ 0.25 WM,
146.7 þ 14.1 nmol/mg/min and 23.6 þ 2.7 min31 (n = 3; the
molecular mass used for Rho-kinase was 160.8 kDa), respec-
tively. Wild-type His-tagged CPI-17 (rH-CPI-17) was
phosphorylated by Rho-kinase to 1.29 þ 0.33 mol of P/mol
of recombinant and substitution of Thr38 to Ala (rH-CPI-
17T38A) resulted in decreased phosphorylation to 0.32 þ 0.01
mol of P/mol of mutant (Fig. 1B). These results indicate
that Rho-kinase can phosphorylate Thr38 on CPI-17 which
is the inhibitory phosphorylation site for PKC [9].
To con¢rm that Rho-kinase phosphorylates Thr38 on CPI-
17, a rabbit polyclonal antibody which recognizes phosphor-
ylation of CPI-17 at Thr38 (pCPI-17T38) was prepared. As
shown in Fig. 2, native CPI-17 phosphorylated by PKC
(lane 2) or Rho-kinase (lane 3) was recognized by pCPI-
17T38. Wild-type rH-CPI-17 phosphorylated by Rho-kinase
was detected (lane 4), while rH-CPI-17T38A phosphorylated
by Rho-kinase was not (lane 5). These results are consistent
with the phosphorylation of CPI-17 at Thr38 by Rho-kinase.
The e¡ects of unphosphorylated CPI-17 and CPI-17
phosphorylated by Rho-kinase on the activity of MP were
investigated. Native CPI-17 phosphorylated by Rho-kinase
showed a dose-dependent inhibition of MP holoenzyme activ-
ity with an IC50 value of 36.9 þ 5.4 nM (Fig. 3A). The un-
Fig. 1. Phosphorylation of CPI-17 by Rho-kinase. (A) Native CPI-
17; (B) wild-type rH-CPI-17 (a) and rH-CPI-17T38A (b). Each pro-
tein (10 WM) was phosphorylated by Rho-kinase for the indicated
time under the conditions as described in Section 2. Error bars indi-
cate means þ S.E.M. (n = 3).
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phosphorylated CPI-17 showed a considerably weaker inhib-
itory e¡ect and MP activity was reduced to 51.3 þ 2.9% at
1 WM unphosphorylated CPI-17 (Fig. 3A). As shown in
Fig. 3B, wild-type recombinant His-tagged CPI-17 (rH-CPI-
17) showed a similar phosphorylation-dependent inhibition of
MP activity (IC50 = 46.0 þ 8.4 nM). Inhibition of MP activity
by the Thr38 to Ala mutant (rH-CPI-17T38A) was similar to
unphosphorylated CPI-17 and inhibitory potency was not in-
creased following phosphorylation by Rho-kinase (Fig. 3B).
4. Discussion
CPI-17 was discovered as a heat-stable inhibitory protein of
PP1 and it was shown that its inhibitory potency was in-
creased by phosphorylation with PKC, or an unidenti¢ed en-
dogenous kinase [9]. It was subsequent shown that CPI-17
phosphorylated by PKC induced contraction of permeabilized
vascular smooth muscle at submaximal Ca2 concentrations
with an accompanying increase of myosin phosphorylation
[10,11]. An unusual feature of CPI-17, compared to inhibitor
1 and inhibitor 2, is that it can inhibit both the free catalytic
subunit and holoenzyme of PP1 [9,21]. The inhibitory phos-
phorylation site on CPI-17 was identi¢ed as Thr38 [9]. From
our studies, using the point mutant of CPI-17 (Thr38 to Ala)
and the phosphorylation-state-speci¢c antibody, it was found
that Rho-kinase also phosphorylates this site and induces a
more potent inhibitory form of CPI-17. Potency of inhibition
following phosphorylation by Rho-kinase increased about 100
fold, whereas a slightly higher increase was reported for PKC
[9,18,21]. Some di¡erences in sensitivity for various reports
could partly be due to various assay conditions. CPI-17 is
expressed speci¢cally in smooth muscle. It is relatively high
in aorta and bladder and the expression of CPI-17 in other
smooth muscles may vary [12,18]. In aorta, the concentration
of CPI-17 was estimated to be at least 0.3 WM [21], which is
within the range of its Km for Rho-kinase (1.4 WM). An in-
hibitor similar to CPI-17, but found in many tissues, was
reported recently and was termed phosphatase holoenzyme
inhibitor (PHI) with two isoforms, 1 and 2 [22]. Phosphory-
lation of PHI-1 by PKC enhances the inhibitory potency
about 50-fold. It is not known if PHI-1 or -2 can be
phosphorylated by Rho-kinase.
It is accepted that a major mechanism responsible for Ca2
sensitization in smooth muscle involves inhibition of MP by a
G-coupled mechanism(s). There is strong evidence indicating
RhoA [3] and its downstream partner, Rho-kinase [3,5,6]. In
support of this, it is known that Rho-kinase inhibitors, such
as Y-27632 and HA-1077, block agonist-induced Ca2 sensi-
tization in smooth muscle [23^26]. One mechanism to account
for the role of Rho-kinase is that it phosphorylates MYPT1
and inhibits MP activity. It was shown that thiophosphoryla-
tion by Rho-kinase of Thr695 on MYPT1 (chicken isoform) is
critical for inhibition in vitro and that this residue was
phosphorylated in cultured ¢broblasts following lysophospha-
tidic acid stimulation [7]. In cultured smooth muscle cells, it
was also proposed that RhoA and its downstream target,
Rho-kinase, mediated MYPT1 phosphorylation and inhibi-
tion of MP activity [27].
This study suggests another potential role for Rho-kinase,
namely that it could inhibit MP activity by phosphorylation
of CPI-17. Thus, in those smooth muscles in which CPI-17 is
expressed, there could be two RhoA/Rho-kinase-dependent
mechanisms to inhibit MP, i.e. phosphorylation of either
MYPT1 or CPI-17. Recently, it was reported that stimulation
of intact and permeabilized smooth muscle by histamine gen-
erated higher levels of CPI-17 phosphorylation at Thr38 com-
pared to phenylephrine stimulation [12]. Both PKC and Rho-
kinase inhibitors reduced force and CPI-17 phosphorylation
on stimulation with histamine. The phenylephrine-induced
force was more sensitive to the Rho-kinase inhibitor. The
possibility of di¡erent signaling pathways for histamine and
phenylephrine therefore was raised and it was suggested that
both PKC and Rho-kinase may function in parallel to phos-
phorylate CPI-17. Distinct signaling pathways for PKC and
Rho-kinase are not unexpected but the situation becomes
more complex when proposing two substrates for Rho-kinase.
It is not known how inhibition of MP by phosphorylation of
MYPT1 and/or CPI-17 is integrated and obviously future
studies are required to resolve this issue.
In summary, the results presented above provide evidence
for the in vitro phosphorylation of CPI-17 by Rho-kinase and
a concurrent increase in inhibitory potency towards MP.
Therefore, it is suggested that two RhoA/Rho-kinase-depen-
dent mechanisms may contribute to inhibition of MP activity,
i.e. phosphorylation of MYPT1 and phosphorylation of CPI-
17. It is not known if the two mechanisms are exclusive or
Fig. 2. Immunoblot analysis of CPI-17 phosphorylated by Rho-ki-
nase and PKC using site- and phosphorylation state-speci¢c anti-
body. Lane 1, unphosphorylated native CPI-17; lane 2, native CPI-
17 phosphorylated by PKC (1.2 mol P/mol protein); lane 3, native
CPI-17 phosphorylated by Rho-kinase (0.9 mol P/mol protein); lane
4, wild-type rH-CPI-17 phosphorylated by Rho-kinase (1.3 mol
P/mol protein); lane 5, rH-CPI-17T38A phosphorylated by Rho-ki-
nase (0.27 mol P/mol protein). Samples were subjected to SDS^
PAGE followed by Western blot with pCPI-17T38A (upper panel,
500 ng of protein in each lane) and with anti-CPI-17 antibody (low-
er panel, 100 ng of protein in each lane).
Fig. 3. E¡ect of CPI-17 on MP activity. (A) E¡ects of native CPI-
17 unphosphorylated (a) and phosphorylated (b) by Rho-kinase.
(B) E¡ect of wild-type rH-CPI-17 (circle) and rH-CPI-17T38A (trian-
gle) unphosphorylated (open symbols) or phosphorylated (closed
symbols) by Rho-kinase. Error bars indicate means þ S.E.M. (n = 3).
The phosphatase activity in the absence of CPI-17 was expressed as
100%.
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operate synergistically and participation of the two mecha-
nisms may vary with the agonist used and the identity of
the smooth muscle.
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